A5037900422- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Childhood Cancer Survivors' Quality of Life
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- FOXO transcription factor regulation
- Meningioma and schwannoma management
- Circular RNAs in diseases
- Chromatin Remodeling and Cancer
- Phagocytosis and Immune Regulation
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Brain Metastases and Treatment
- Ultrasound and Hyperthermia Applications
- ATP Synthase and ATPases Research
- Ferroptosis and cancer prognosis
- Microtubule and mitosis dynamics
- Nanoparticle-Based Drug Delivery
- MRI in cancer diagnosis
- Histone Deacetylase Inhibitors Research
- Cancer, Lipids, and Metabolism
- MicroRNA in disease regulation
- Genetics and Neurodevelopmental Disorders
- Pituitary Gland Disorders and Treatments
Princess Máxima Center
2018-2025
University Hospital of Geneva
2024
University of Amsterdam
2012-2023
Vrije Universiteit Amsterdam
2012-2022
Emma Kinderziekenhuis
2020-2022
Amsterdam University Medical Centers
2012-2022
Cancer Center Amsterdam
2011-2021
Amsterdam UMC Location Vrije Universiteit Amsterdam
2009-2019
University of Colorado Denver
2018
Children's Hospital Colorado
2018
Purpose Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with median survival of < 1 year. The International and European Society for Pediatric Oncology DIPG Registries collaborated to compare clinical, radiologic, histomolecular characteristics between short-term survivors (STSs) long-term (LTSs). Materials Methods Data abstracted from registry databases included patients North America, Australia, Germany, Austria, Switzerland, the Netherlands, Italy, France, United...
Although diffuse intrinsic pontine glioma (DIPG) carries the worst prognosis of all pediatric brain tumors, studies on prognostic factors in DIPG are sparse. To control for confounding variables studies, which generally include relatively small patient numbers, a survival prediction tool is needed. A multicenter retrospective cohort study was performed Netherlands, UK, and Germany with central review clinical data MRI scans children DIPG. Cox proportional hazards backward regression used to...
Pediatric high-grade gliomas (pHGG), including diffuse intrinsic pontine (DIPG), are the leading cause of cancer-related death in children. While it is clear that surgery (if possible), and radiotherapy beneficial for treatment, role chemotherapy these tumors still unclear. Therefore, we performed an vitro drug screen on primary glioma cells, three DIPG cultures, to determine sensitivity tumours, without possible confounding effect insufficient delivery. This revealed a high cytotoxicity...
Purpose To evaluate the prevalence of, and risk factors for, early endocrine disorders in childhood brain tumor survivors (CBTS). Patients Methods This nationwide study cohort consisted of 718 CBTS who were diagnosed between 2002 2012, survived ≥ 2 years after diagnosis. with craniopharyngeoma or a pituitary gland excluded. Results all investigations, which performed at diagnosis during follow-up, collected from patient charts. Multivariable logistic regression was used to associations...
Dannis G. van Vuurden 1 , Esther Hulleman Olga L.M. Meijer Laurine E. Wedekind Marcel Kool 2 Hendrik Witt 2,3 W. Peter Vandertop 4 Thomas Würdinger 4,5 David P. Noske Gertjan J.L. Kaspers 6 and Jacqueline Cloos 6,7 Department of Pediatric Oncology / Hematology, Neuro-oncology Research Group, Cancer Center Amsterdam, VU University Medical Center, the Netherlands Molecular Genetics Childhood Brain Tumors, German (DKFZ), Heidelberg, Germany 3 Hematology Oncology, Heidelberg Hospital,...
Predictive tools for guiding therapy in children with brain tumors are urgently needed. In this first molecular drug imaging study children, we investigated whether bevacizumab can reach diffuse intrinsic pontine glioma (DIPG) by measuring the tumor uptake of 89Zr-labeled PET. addition, evaluated safety procedure and determined optimal time imaging. Methods: Patients received 89Zr-bevacizumab (0.1 mg/kg; 0.9 MBq/kg) at least 2 wk after completing radiotherapy. Whole-body PET/CT scans were...
Diffuse intrinsic pontine glioma (DIPG) is a rare clinically, neuro-radiologically, and molecularly defined malignancy of the brainstem with median overall survival approximately 11 months. Our aim to evaluate current tendency for its treatment in Europe order develop (inter)national consensus guidelines.Healthcare professionals specialized DIPG were asked fill an online survey questions regarding usual strategies at diagnosis disease progression their countries and/or centers,...
Abstract Purpose: Diffuse intrinsic pontine glioma (DIPG) is an incurable type of pediatric brain cancer, which in the majority cases driven by mutations genes encoding histone 3 (H3K27M). We here determined preclinical therapeutic potential combined AXL and HDAC inhibition these tumors to reverse their mesenchymal, therapy-resistant, phenotype. Experimental Design: used public databases patient-derived DIPG cells identify putative drivers mesenchymal transition tumors. Patient-derived...
Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric disease. Thus far, no therapeutic agent has proven beneficial in the treatment of this malignancy. Therefore, conventional DNA-damaging radiotherapy remains standard treatment, providing transient neurologic improvement without improving probability overall survival. During radiotherapy, WEE1 kinase controls G(2) cell-cycle checkpoint, allowing for repair irradiation (IR)-induced DNA damage. Here, we show that one highest...
Pineoblastoma is a rare pineal region brain tumor. Treatment strategies have reflected those for other malignant embryonal tumors.Original prospective treatment and outcome data from international trial groups were pooled. Cox regression models developed considering elements as time-dependent covariates.Data on 135 patients with pineoblastoma aged 0.01-20.7 (median 4.9) years analyzed. Median observation time was 7.3 years. Favorable prognostic factors age ≥4 (hazard ratio [HR]...
The role of the VEGF inhibitor bevacizumab in treatment diffuse intrinsic pontine glioma (DIPG) is unclear. We aim to study biodistribution and uptake zirconium-89 ((89)Zr)-labeled DIPG mouse models. Human E98-FM, U251-FM cells, HSJD-DIPG-007-FLUC primary cells were injected into subcutis, pons, or striatum nude mice. Tumor growth was monitored by bioluminescence imaging (BLI) visualized MRI. Seventy-two 96 hours after (89)Zr-bevacizumab injections, mice imaged positron emission tomography...
With more children surviving a brain tumor, neurocognitive consequences of the tumor and its treatment become apparent, which could affect psychosocial functioning. The present study therefore aimed to assess functioning pediatric survivors (PBTS) in detail. Psychosocial PBTS (8–18 years) with parent-reported complaints was compared normative data on health-related quality life (HRQOL), self-esteem, adjustment, executive (one-sample t tests) sibling control group fatigue (independent-samples...
Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in survival. It therefore time for international collaboration DIPG research, to provide new hope children, parents medical professionals fighting DIPG. In first step towards collaboration, 2011, network biologists clinicians working the field was established within European...